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Abstract
Estrogen receptor-positive breast cancer is a highly prevalent but heterogeneous dis-
ease among women. Advanced molecular stratification is required to enable individually
most efficient treatments based on relevant prognostic and predictive biomarkers. First
objective of our study was the hypothesis-driven discovery of biomarkers involved in
tumor progression upon xenotransplantation of Luminal breast cancer into humanized
mice. The second objective was the marker validation and correlation with the clinical
outcome of Luminal breast cancer disease within the GeparTrio trial. An elevated mdm2
Abbreviations: BC, breast cancer; BM, bone marrow; DFS, disease free survival; ER, estrogen receptor; FISH, fluorescence in situ hybridization; hPDX, human patient derived xenotransplant;
HSCs, hematopoietic stem cells; HTM, humanized tumor mice; k.d., knock-down; NSG, NOD scid gamma; OS, overall survival; TICs, tumor initiating cells; WGA, whole genome amplification.
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gene copy number was associated with enhanced tumor growth and lung metastasis in
humanized tumor mice. The viability, proliferation and migration capacity of inherently
mdm2 positive breast cancer cells in vitro were significantly reduced upon mdm2 knock-
down or anti-mdm2 targeting. An mdm2 gain significantly correlated with a worse DFS
and OS of Luminal breast cancer patients, albeit it was also associated with an enhanced
preoperative pathological response rate. We provide evidence for an enhanced Luminal
breast cancer stratification based on mdm2. Moreover, mdm2 can potentially be utilized
as a therapeutic target in the Luminal subtype.
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What's new?
Breast cancer is extremely heterogeneous, even within subtypes. For best outcomes, therapies
must be tailored to the molecular profile of the particular tumor. Here, the authors searched for
new biomarkers in ER-positive breast cancer using a humanized tumor mouse (HTM) model,
which replicates a functional human immune system. They discovered that amplification of a
gene, mdm2, was associated with tumor progression. Treatment with agents that inhibit mdm2
slowed down cell proliferation, viability and migration of cancer cells in vitro. Clinical testing for
mdm2 status could help improve targeted treatment for these patients.
1 | INTRODUCTION
Humanized tumor mice (HTM) represent a powerful animal model in
cancer research to carry out treatment studies under human-like con-
ditions. Upon xenotransplantation, either based on human cancer cell
lines (HTM) or on patient-derived primary tumors (hPDX), tumor
growth takes place in the presence of a functional human immune
system. Lymphopoiesis and myelopoiesis occurs upon neonatal trans-
plantation of human cord blood-derived hematopoietic stem cells
(HSCs), which ensures a considerable degree of immunological toler-
ance against mouse tissue.1 Tumor transplantation into NOD scid
gamma (NSG) mice can be done, for example, intrahepatically, subcu-
taneously or orthotopically (eg, into the mammary fat pad), which has
an impact on tumor cells and tissues to engraft and to maximally adapt
to a species-foreign environment. Only a successful engraftment and
an efficacious adaption enable the most genuine human tumor growth
and progression in mice, which is an essential basis for relevant pre-
clinical treatment studies.
So called tumor initiating cells (TICs) have been found to come
along with an enhanced capacity to colonize in immunodeficient
mice.2 The initiation of tumor engraftment and tumor growth is evi-
dently associated with stem cell characteristics, that is, the ability of
malignant cells to self-renew, to propagate and to differentiate.
Although, a number of markers are known to be associated with
tumor initiation and propagation, the characterization and identifica-
tion of TICs with an enriched malignant potential is challenging since
tumor initiating and stem cells show a dynamic physiology and varying
genotypes and phenotypes in individual tumor types and subtypes.
Among solid tumors breast cancer (BC) is on the cellular and molec-
ular level a highly heterogeneous disease.3 The description of molecular
portraits of humane BC about 20 years ago4 led to the categorization of
five major subtypes, which are mainly differentiated by their proliferation
activity and the amount of hormone-receptor as well as HER2-receptor
expression. The main taxonomic subtypes include so called “Luminal-A”
and “B,” “Luminal-HER2-positive,” “HER2-enriched” and “triple nega-
tive” (ie, absence of hormone and HER2-receptor expression) BC.3 These
BC subtypes markedly differ in terms of course and outcome of disease
as well as therapy options. In addition, there is a substantial heterogene-
ity even within individual BC categories with respect to disease progres-
sion and treatment response. For example, estrogen-receptor
(ER) positive tumors represent indeed the largest BC subgroup (about
70% of all BCs) from which about 70% of all BCs are being assigned to
the Luminal-A and about 30% to the Luminal-B type.5 While Luminal-A
typically comes with a pronounced ER expression but rather low-
proliferation capacity the Luminal-B subtype is characterized by a lower
ER expression, higher grading (ie, less tissue differentiation) and
enhanced proliferation activity. Based on these symptomatic traits
Luminal-B BC shows better response rates to cytotoxic (ie, antip-
roliferative) treatments while Luminal-A BC shows higher sensitivity to
endocrine (ie, hormone) therapies.3,6,7 Accordingly, complementing an
endocrine treatment of Luminal-A BC by chemotherapy is likely to result
in an overtreatment. Nevertheless, besides generally good treatment
responses of Luminal BC an appreciable number relapses are seen in
both groups,8 but more often in Luminal-B. Thus, further stratification of
Luminal BC will help to render more precisely discrete prognoses for BC
patients and to identify individually most effective treatment modalities.
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Moreover, an enhanced stratification will contribute to therapy
de-escalation wherever possible.
In our study we generated hPDX by xenotransplantation of immuno-
deficient, humanized NSG mice with primary ER-positive BC tissues. We
determined the engraftment efficiency and evaluated tumor growth and
progression. These parameters were correlated to phenotypic and geno-
typic tumor characteristics. We applied immunohistochemistry and flow-
cytometry for tumor and immune cell characterization and used panel
sequencing of BC relevant genes to identify genomic aberrations, which
were potentially associatedwith tumor growth, dissemination andmetasta-
sis. Most strikingly, we identified a gain of mouse double minute-2 and
4 homolog (mdm2/mdm4) gene and/or a mutation of the TP53 locus to be
associated with a higher engraftment efficiency in hPDX. Moreover, we
observed an enhanced tumor progression and formation of lung metastasis
in these mice bearing an mdm2 gain. Remarkably, lung metastasis dissemi-
nated cells in the bone marrow (BM) of tumors with mdm2 amplification
were strongly associated with an elevated c-Met and CD44 expression.
In vitro experiments revealed a reduced cell vitality, proliferation andmigra-
tion capacity of BC cells with inherentmdm2 amplification uponmdm2pro-
tein knockdown (k.d.) or mdm2 inhibition. The assessment of mdm2 gene
copy number via fluorescence-in situ-hybridization (FISH) on ER-positive
BC subcohort derived from the GeparTrio trial,9 retrospectively disclosed a
shortened disease free (DFS) and overall survival (OS) of BC patients who
harbored anmdm2 gain compared to thosewithoutmdm2 alteration.
A prospective validation of mdm2, c-Met and CD44 as prognostic
biomarkers in ER-positive BC can be considered to complement the
clinicopathological diagnostics and thereby might enhance the stratifi-
cation of Luminal BC. Prospectively, mdm2 might not only serve as a
prognostic, but also as a predictive marker and therapeutic target in
Luminal BC, even though further systematic preclinical treatment
studies in vivo are required.
2 | MATERIALS AND METHODS
2.1 | Isolation of hematopoietic stem cells from
umbilical cord blood
In order to humanize mice, CD34+ hematopoietic stem cells (HSC)
were isolated from the umbilical cord blood based on the procedure
described the first time in 2011.1 More information is given in the
Supporting Information Material.
2.2 | Tumor tissues processing for mouse
transplantation
All patient-derived samples included in the study were premenopausal
or postmenopausal women diagnosed with primary or metastatic BC
and underwent surgery at the Department of Gynecology (University
of Regensburg). Fresh, solid tumor material was removed under sterile
conditions by a pathologist upon the Institute of Pathology at the
(University of Regensburg). The tumor was collected in prewarmed
basal medium (DMEM/F12, 1% HEPES, 1% Pen/Strep and 1%
Amphotericin B) in a petri dish and minced into fragments of
2  2 mm. The tumor fragments were either transplanted subse-
quently into NSG mice or cryopreserved.
2.3 | Generation of NSG based hPDX
Patient tumor samples were prepared as described above and the
transplantation was carried out in 7 to 8 weeks old, virgin, non-
ovariectomized, humanized female NOD.Cg-Prkdcscid Il2rγtm1Wjl/SzJ
(NSG) mice according to the protocol established by Al-Hajj.10 Briefly,
mice were disinfected at the mammary fat pad and through a small
incision, the tumor fragments were transplanted into the inguinal right
fat pad and 50 μL of Matrigel (R&D Systems, Inc., Minneapolis, Minne-
sota) was added together with a s.c. 0.18 mg 17ß-estradiol pellet
(Innovative Research of America, Florida).
In addition to primary patient-derived tumor tissues three previously
established patient-derived xenograft (PDX) tumors provided by
Dr. Marangoni (Institute Curie, Paris, France) were sent to our laboratory
(PT-S2, PT-S3 and PT-S4) and preprocessed as described above.11-14
Another two PDX tumors (PT-CTC and PT-E2) were provided by Prof.
Andreas Trumpp (HI-Stem, Heidelberg, Germany).2,15 These mice were
transplanted by s.c. neonatal transplantation of 2  106 tumor cells
diluted in 20 μL DMEM and 10 μLMatrigel using a BD Safety Glide Insu-
lin syringe. The PDX models were monitored for 12 months and eutha-
nized beforehand if maximum tumor size (15 mm) was reached or any
signs of sickness occurred. The previously established PDX tumors pro-
vided by the collaboration partners were not initially analyzed with
respect to mdm2, mdm4 or TP53 but randomly selected for our study.
Just like the other successfully engrafted tumor samples used here they
were retroactively subjected to panel sequencing.
2.4 | Flow cytometric analyses of immune cell
reconstitution and tumor phenotyping from hPDX
Phenotyping of tumor and immune cells derived from hPDX was done
by flow cytometry using a FACS Canto-II flow cytometer run by the
Diva software v7.0 (BD Biosciences, San Jose, California) equipped
with a blue (488 nm), violet (405 nm) and red (633 nm) laser excita-
tion. Unspecific binding was blocked by incubating the cells in 1%
mouse serum for 10 minutes and appropriate mouse immunoglobulin
antibodies were used as isotype controls for all staining. Antibodies
used for flow-cytometric analyses are specified in the Supporting
Information Material.
2.5 | Embedding of HTM-derived tumor samples
and immunohistochemistry
Tissue specimens (tumor and lung) were fixed with 4% formalin from
which 1.5-μm paraffin sections were prepared. Specimens were
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deparaffinized and pretreated by microwave heating for 30 minutes
at 320 W in 0.1 M citrate buffer adjusted to pH 7.3. The
immunostainings were automatically performed on a Ventana Nexes
autostainer (Ventana, Tucson, Arizona) by using the streptavidin-bio-
tin-peroxidase complex method and 3,30-diaminobenzidine as chro-
mogen. The autostainer was programmed based on the instructions
given by the iView DAB detection kit (Ventana). Antibodies used for
immunohistochemistry are specified in the Supporting Information
Material.
2.6 | mdm2 knockdown and anti-mdm2 (AMG232)
treatment
ZR-75-1 cells (RRID: DVCL_0588, ATCC via LGC Standards GmbH,
Wesel Germany) were incubated under standard culture conditions in
RPMI-1640 medium supplemented with phenol red and 5% FCS (PAN
Biotech, Aidenbach, Germany). mdm2 expression in ZR-75-1 cells was
knocked down using ON TargetPlus smart pool siRNA in
DharmaFECT-1T-2011-02 (Horizon Dharmacon, Lafayette, Colorado).
Untreated cells and cells treated with nontargeting Pool siRNA were
used as control. ZR-75-1 were seeded at a density of 400 000 cells
per T25 tissue flask and cultured in RPMI-1640 medium sup-
plemented with 5% FCS overnight. On the following day, the medium
was replaced with RPMI-1640 medium supplemented with 1% FCS
and the transfection was performed according to the manufacturer’s
protocol. On day four after transfection, the cells were either
harvested with trypsin-EDTA for further experiments or lyzed with
50 μL lysis buffer (100 μL cell lysis buffer, 10 μL PMSF [1 mM], 10 μL
HALT protease inhibitor and 880 μL aqua dest. for protein biochemi-
cal analysis.
For AMG232 treatment studies, ZR-75-1 were seeded at a den-
sity of 400 000 cells per T25 tissue flask and cultured in RPMI-1640
medium supplemented with 5% FCS overnight. The next day the
medium was changed and the cells treated with 0.1 or 1 μM AMG232
inhibitor (Axon Medchem BV, Groningen, The Netherlands). DMSO-
treated cells and cells without treatment served as control. The cells
were exposed for 48 and 72 hours to AMG232 and then harvested
with trypsin-EDTA for further analyses.
ZR-75-1 cells were authenticated by short-tandem repeat profil-
ing at the beginning of the study and within the last 3 years (DSMZ,
Braunschweig, Germany). In addition, all experiments were performed
with mycoplasma-free cells.
2.7 | Migration assay
Determination of tumor cell wound closure and migratory properties
were analyzed by a wound-healing assay. In brief, 80 000 cells were
seeded in each chamber of a 2-Well Culture-Insert (35 mm) (Ibidi,
Gräfelfing, Germany) fixed in a 6-well plate. The cells were allowed to
adhere overnight. Next day the insert was removed, the cells were
washed with PBS to remove cell debris and fresh medium was added
to the well. The cell scratch was visualized at 20-fold magnification by
light microscopy and documented at time intervals between 6 and
216 hours after chamber removal. Closure of the scratch area was cal-
culated by the AxioVision software (Ver. 4.4, Carl Zeiss GmbH,
Göttingen, Germany).
2.8 | Western blotting
Western blotting was performed exactly as described recently.16 A
brief description of the procedure is given in the Supporting Informa-
tion Material.
2.9 | Flow cytometric analysis of cell proliferation
and cellular apoptosis
Upon harvesting by trypsinization and separation the cells were
washed twice with PBS fixed and permeabilized in cooled in MeOH
(70%). After overnight incubation, cells were washed twice with PBS,
incubated for 20 minutes in the presence of RNAase at 37C and
finally stained with 1 μg/mL DAPI 30 minutes prior to analysis. DNA
histograms were quantified using the ModFit LT 3.2 software (Verity
Software House, Topsham, Maine) upon discrimination of cell dou-
blets, aggregates and debris via pulse processing.
For the analysis of apoptosis, adherent cells and those of the
supernatant were harvested, pooled and suspended in 75 μL Annexin-
V-FITC solution containing 5 μL Annexin-V-FITC and 70 μL binding
buffer. After 20 minutes of incubation on ice in the dark, the cells
were centrifuged and resuspended in 200 μL binding buffer. Prior to
the measurement, the DAPI dye was added to a final concentration of
0.1 μg/mL).
2.10 | Low pass sequencing of DTC
Single cell whole genome amplification (WGA) products were pre-
pared for copy number variant (CNV) analysis by Ampli1 LowPass kit
for Illumina (Menarini Silicon Biosystems, Pennsylvania).17 Briefly,
starting from purified primary Ampli1 WGA product, barcoded librar-
ies compatible with Illumina systems were generated. The libraries
were quantified using the Qubit dsDNA HS reagent kit and the Qubit
3.0 Fluorometer. Additionally, the average fragment sizes of the librar-
ies were assessed using the Agilent High Sensitivity DNA Kit on the
Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa Clara,
California). Subsequently, samples were sequenced on an Illumina
MiSeq device with MiSeq Reagent Kit v3 (150-cycle) (Illumina, San
Diego, California). CNV profiles were generated using an automated
in-house pipeline which contains in brief the following steps: Trim-
ming of raw FASTQ files with BBDuk 38.84 (JGI DataScience, BBtools
software suite 2019 https://jgi.doe.gov/data-and-tools/bbtools), read
decontamination using BioBloom Tools 2.0.1318 mapping with
Burrows-Wheeler Aligner (BWA-MEM algorithm 0.7.17) CNV profile
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generation applying QDNAseq 1.26.0. After each step a quality con-
trol was performed (Table S1).19
2.11 | Panel sequencing
Eight micrometer-thick sections of FFPE primary tumor samples were
analyzed by the Institute of Pathology (Technical University Munich,
Germany) using a three primer pools yielding 617 amplicons covering
mutational hotspot regions located in 353 exons of 59 genes that are
known to be related to breast cancer as previously described.20 Most
relevant steps of the procedure are given in the Supporting Informa-
tion Material. Quality assessment of panel sequencing is given in
Table S2.
2.12 | GeparTrio patients' cohort for mdm2
assessment
The GeparTrio trial (NCT00544765) was a multicenter, prospective,
randomized, phase III trial with the primary goal to evaluate the patho-
logic complete response (pCR) after the treatment with four to six
additional cycles of docetaxel, doxorubicin and cyclophosphamide
(TAC) in patients responding to initially applied two cycles of TAC or
four additional cycles of TAC compared to four cycles of vinorelbine
and capecitabine for nonresponders to the initial two cycles of TAC.
Patients with untreated primary breast carcinoma (T2-4, N0-3 and
M0) were included.21 pCR was defined as the absence of residual
invasive and noninvasive disease in any excised breast or regional
node tissue. For the analysis performed by our study we selected
exclusively tissue specimens previously diagnosed as Luminal, that is,
ER-positive BC. The categorization of Luminal-A and Luminal-B was
based on a 20% Ki67 cut-off.22,23 Overall, 502 Luminal BC specimens
were subjected to our study. Two hundred and forty-five (48.8%)
were attributed to the Luminal-A and 257 (51.2%) to Luminal-B sub-
cohort. Relevant clinico-pathological characteristics of the patients'
cohort are listed in Table S3. In addition, an assignment to samples
with and without an mdm2 gain is given.
2.13 | Selection of tissue samples, preparation of
tissue microarrays and FISH
FISH on tumor tissue samples of the GeparTrio cohort was applied to
tissue microarrays generated by the Institute of Pathology (Philipps-
University Marburg). A ZytoLight SPEC MDM2/CEN12 dual color
probe (ZytoVision GmbH, Bremerhaven, Germany) was used as previ-
ously described and samples from excised from HTM were done anal-
ogously.24 More details are given in the Supporting Information
Material. FISH results were categorized into the following Scoring sys-
tem: Score 1: ≈ 2 mdm2 gene signals, Score 2: ≈ 5 mdm2 hybridiza-
tion signals and Score 3: mdm2 gain of ≥10. The CEN12 marker
signals were disregarded since CEN12 alterations (either gains or
losses) were not observed.
2.14 | Statistical analysis
DFS and OS were defined as the time (in months) from random
assignment to the event; patients without event were censored at the
time of the last contact.9,25 Events for DFS were any locoregional
(ipsilateral breast or local/regional lymph nodes) recurrence of disease,
any contralateral breast cancer, any distant recurrence of disease, any
secondary malignancy or death as a result of any cause, whichever
occurred first. Event for OS was death due to any cause. Statistical
tests applied are described in detail in the Supporting Information
Material.
3 | RESULTS
3.1 | mdm2 (or mdm4) gene amplification or a loss
of TP53 is associated with engraftment in Luminal-B
specific PDX
A total of seven Luminal-B specific humanized PDX were generated
based on defined ER, progesterone receptor (PR) and HER2 expres-
sion patterns as given in Figure 1A. Accordingly, all PDX samples were
ER-positive, four were ER/PR-double-positive and two samples were
ER/HER2-double positive. Twenty-two tumor samples of Luminal-B
patients derived from the Department of Gynecology at the Univer-
sity of Regensburg were transplanted in NSG mice from which two
tumors led to a stable and retransplantable PDX model (PT-S1 and
PT-E1). Overall, we achieved an engraftment rate of approximately
10%. Three previously established PDX models (PT-S2 [alias HBCx3],
PT-S3 [alias HBCx22] and PT-S4 [alias HBCx34]; Institute Curie, Paris,
France12) and two other models established at the German Cancer
Research Center Heidelberg (PT-CTC and PT-E22) were transferred
into humanized mice and further evaluated.
Analysis of genomic alterations in these PDX models by panel
sequencing revealed that all successfully engrafted tumors share
genomic alterations within the mdm2/mdm4/TP53 axis. More specifi-
cally, samples with the capacity for engraftment, harbored either an
mdm2 or mdm4 gene amplification and/or a loss or mutation of TP53
as given in Figure 1A. Two models showed an additional HER2 gene
amplification. mdm2 FISH confirmed mdm2 gene amplifications as ini-
tially determined by panel sequencing and revealed either ≈5 gene
copies (ie, Score 2) or ≥10 copies (ie, Score 3) as defined in Section 2.
Notably, as analyzed by FISH 95.0% (1/20) of not-engrafted tumor
samples had no mdm2 gene amplification (ie, Score 1, data not
shown). Hereinafter, mdm2 amplified PDX models are referred to as
mdm2Amp and “mdm2 wildtype” models are referred to as mdm2WT.
Since the PT-E1 model was unique due to an inherent mdm4 alter-
ation we excluded this model from further analysis.
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3.2 | mdm2 amplified PDX was associated with an
increased tumor volume and enhanced lung
metastases in hPDX
Tumor samples from each PDX model were transplanted into NSG in
the presence of a human immune system resulting in hPDX. The
tumor volume in all four hPDX-mdm2Amp mouse models were signifi-
cantly increased in comparison to hPDX-mdm2WT (Figure 1B,C;
P = .0023). A correlation between the origin of tumor models and
tumor volume could be precluded. Immunohistochemical staining of
cytokeratin 18 (CK18), ER and PR confirmed the origin of the
implanted human tumor and Ki-67 expression represents the prolifer-
ative capacity of the tumor tissue (Figure 1D).
CK18 is highly expressed in epithelial cells of Luminal-B breast can-
cer. It served as a marker to identify tumor cells in distant organs
(ie, metastases in the lung, Figure 1E). In addition, the number of animals
with lung metastasis was determined based on CK18 staining. Besides
an increased tumor growth in mdm2Amp, mdm2 amplification correlated
with a significantly enhanced potential to develop lung metastasis.
Lung metastases were detected in 2 of 12 hPDX-mdm2wt mice
and in 17/22 hPDX-mdm2Amp mice (Figure 1E; P = .0011). Enhanced
lung metastasis is seen in all mdm2Amp mice and does not depend on
individual mouse models or the origin of individual tumors used for
the generation of hPDX mice.
Notably, highly mdm2 amplification (Score 3) seems to be associ-
ated with increased metastases within the mdm2Amp group (Score
3 = 100% metastases; Score 2 = 50% metastases formation;
Figure 1E). mdm2 gene amplification was also detectable in lung
metastases (an example identified by FISH is given in the lower part
of Figure 1E).
F IGURE 1 Origin of seven Luminal-B humanized PDX models used in our study and tumor growth and lung metastases of mdm2WT and
mdm2Amp transplanted hPDX. (A) Nomenclature of seven Luminal-B hPDX models use in our study is listed. In addition, genomic alterations of
HER2, mdm2, mdm4 and TP53 found upon successfully engrafted PDX tumor samples and the respective mdm2 scores are given. CTC, generated
from circulating tumor cells from the peripheral blood; E, generated from metastatic tumor effusion; PT, primary tumor material; S, generated
from solid tumor. (B) Representative tumor samples from mdm2WT and mdm2Amp are displayed. (C) Tumor volume of mdm2WT and mdm2Amp in
hPDX was assessed (π/6  length  width  height) and significances between both groups were calculated by Student's t-test (P = .0023). The
average days of survival post tumor transplantation of each model are indicated in brackets. (D) Exemplary tumor samples stained for CK18,
estrogen receptor (ER), Ki-67 and progesterone receptor (PR) are shown for PDX PT-S3. (E) Representative images of CK18 and ER expression on
lung metastases in mdm2Amp transplanted PDX PT-S1 are displayed (upper panel). Bars represent 100 μm. Lung tissues from individual hPDX
models were stained with CK18 specific antibodies and the number of mice with detectable tumor cells was counted. The difference in incidence
for lung metastases was calculated using the two-sided Fisher's exact test (P = .0011). An example FISH image of lung metastatic cells (PDX
model PT-S1) with mdm2 gene amplification is shown. (F) Single cells from the lung and the corresponding tumor of mdm2Amp hPDX (PT-CTC,
PT-S1 and PT-S4) were phenotypically analyzed using flow cytometry. Differences were calculated using Sidak's multiple comparisons test
(****P < .0001). (G) CD47+, CD44+ and c-Met+ positive cell populations in tumor and lung tissues of mdm2Amp hPDX were compared and
statistical differences calculated by Student's t-test (*P < .05)
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Single cells isolated from the tumor and the lung of hPDX
mdm2Amp were phenotyped by flow cytometry and revealed a signifi-
cant induction of c-Met and CD44 expression in metastatic tumor
cells in the lung compared to primary tumor cells (P < .0001;
Figure 1F). CD44, CD47 and c-Met were found simultaneously
upregulated in lung metastases of mdm2Amp PDX mice (P = .0252;
Figure 1G).
3.3 | mdm2 gene amplification did not correlate
with the frequency of tumor cell dissemination into
the BM of hPDX
Single DTCs in the BM of mice were detected and quantified based
on a panCK (CK8, CK18 and CK19) staining (Figure S1A). There was
no significant difference in animals with detectable DTCs in the BM
for mdm2Amp and mdm2WT models (P = .2929; Figure S1A) and cells
appeared as single cells or small clusters in both groups. The average
frequency of detectable DTCs in 500,000 BM cells was 3.3 (±0.97
SEM; n = 7). Just like metastatic tumor cells in the lung, DTCs in the
BM showed a significantly increased CD44 and c-Met expression,
which is exemplarily shown for mdm2Amp hPDX “PT-CTC” in
Figure S1B (c-Met: P < .0001; CD44: P < .0001).
DTCs from three different hPDX BM samples and associated sin-
gle cells from the corresponding tumors were isolated and subjected
to low-pass genome sequencing. In contrast to isolated single resident
BM cells, all isolated tumor cells from primary tumor and DTCs
showed copy number aberrations including an mdm2 amplification
(20/20; Figure S1C). However, the mdm2 gene copy number varied in
individual DTCs: One hPDX showed mdm2 amplification also in the
corresponding DTCs, one mouse showed gene amplification in two
out of three DTCs and in one mouse all seven isolated DTCs lacked
amplification (Figure S1C). While CK-negative single cells show a
balanced profile (Figure S1D, upper profile), genomes of all isolated
CK-positive cells have multiple genomic gains (depicted in red) and
losses (depicted in blue). Interestingly, not only the mdm2 gene region
(chromosome 12) showed heterogeneity but also other loci indicated
individual variation in between single cells isolated from the tumor
and the different DTCs from the BM (Figure S1D).
3.4 | mdm2 gene amplification reduced T cell
incidence and maturation in hPDX
Analysis and phenotyping of immune cells was done for the two
mdm2wt and four mdm2Amp models individually (Figure 2). Overall,
Immune cell distribution in mdm2Amp hPDX revealed a significant
reduced T cell fraction (P < .0001) and increased B cell population
(P < .0001) in the spleen (Figure 2A) while variations between individ-
ual hPDX models are visualized. The T cell maturation of CD4+ and
CD8+ was not significantly different within the mdm2wt and the
mdm2Amp group as exemplarily shown for CD4+ T cells (Figure 2B).
Interestingly, mdm2Amp hPDX showed a significantly lower percentage
of PD-1 expression on the CD8+ T cells (Figure 2C, right graph;
F IGURE 2 Human immune cell reconstitution in mdm2WT and mdm2Amp transplanted hPDX. (A,B) Human immune cell distribution of myeloid,
B and T cells, and T cell subsets (naïve, memory, memory effector and terminally differentiated effector memory cells [TEMRA]) in the spleen of
individual mdm2WT and mdm2Amp hPDX models were determined using flow cytometry. (C) Graphs represent the percentage of PD-1 expression
on CD4+ (left graph) and on CD8+ (right graph) T cells in the spleen. The immune subsets (D), T cell subpopulations (E) and PD-1 expression on
CD4+ and CD8+ T cells (F) were analyzed in the tumor. Data are shown as mean ± SEM and significances were analyzed using Sidak's multiple
comparisons test (A, B, D, E) or Student's t-test (C, F). P-values <.05 are indicated in the graphs (*P < .05; ****P < .0001) and numbers of animals in
each group are displayed (n = x) or presented as individual symbol in the graphs
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P = .022) but not on CD4+ T cells (Figure 2C, left graph). The overall
immune cell infiltration in the tumor tissue of ER-positive based hPDX
was low (<1% CD45+ cells; data not shown) and was nearly in the
same low range as the fraction found in the primary tumor tissues of
the tumor patients (Ø 7.83% CD45+ cells ± 1.3 SEM; n = 11; data not
shown). The proportion of human T cells invading into the tumor tis-
sue was also lower in mdm2Amp hPDX compared to mdm2WT hPDX
(Figure 2D; P = .046) while the percentage of naive CD4+ T cells was
significantly higher (Figure 2E; P = .045). No differences could be
detected with respect to CD8+ T cells. Overall, a tendency of reduced
PD-1 expression on CD4+ and CD8+ T cells in mdm2Amp hPDX in the
tumor was seen, especially in the highly amplified (Score 3) hPDX
models PT-S1 and PT-CTC (Figure 2F).
3.5 | mdm2 knockdown and AMG232 based
mdm2 inhibition similarly induced apoptosis and
reduced proliferation in ER-positive BC cells in vitro
The ER-positive cell line ZR-75-1 was treated with anti mdm2 siRNA,
which caused a significant depletion of the mdm2 protein (Figure 3A). In
addition, the FAK activity was diminished upon mdm2 k.d. as indicated
by a reduced phosphorylation, while the total FAK expression was not
affected (Figure 3B). As a consequence of the primary siRNA based
mdm2 k.d. and the mdm2 targeting with 1 μM AMG232 significant frac-
tions of apoptotic cells were observed (Figure 3C, P = .021 and
Figure 3D, P < .0001). Moreover, the cell proliferation capacity was
reduced upon mdm2 k.d. (Figure 3E) as indicated by a reduced S-phase
F IGURE 3 Effects of mdm2 knockdown and mdm2 inhibition by AMG232 in breast cancer cells in vitro. The Luminal-B breast cancer cell line
ZR-75-1 was treated with small-interfering RNA (siRNA) for mdm2 (A, B, C, E, G) or with 0.1 μM and 1 μM AMG232 (D, F, H). (A,B) Western
blotting of mdm2 and FAK/pFAK expression of untreated (ctrl.), no target control RNA (NT ctrl.) or mdm2 specific knockdown by siRNA (mdm2 k.
d.). Significant differences were calculated by Tukey's multiple comparisons test. Apoptosis induction upon mdm2 k.d. (C) and AMG232 treatment
(D) was analyzed by flow cytometry using an Annexin and DAPI staining to allow the differentiation of vital (Annexin DAPI) and dead cells
(Annexin+ and/or DAPI+). Data are shown as mean ± SEM and Dunnett's multiple comparisons test was applied. Cell proliferation was analyzed
upon mdm2 k.d. (E) and AMG232 treatment (F) by flow cytometry and S-phase, G1 and G2 fraction were determined. Data are shown as mean
± SEM and Dunnett's multiple comparisons test was applied. A scratch assay was performed upon mdm2 siRNA (G) or AMG232 (H) treatment
and ZR-75-1 with which cell migration capacity was analyzed over time. Data are shown as mean ± SEM and Dunnett's multiple comparisons test
was applied. Representative images show the time point after 144 hours of incubation. Red bars mark the gap after chamber removal at point
0 hour and the gap of mdm2 k.d./AMG232 treatment after 144 hours. All experiments were performed three times and significances are
indicated in each graph (*P < .05; **P < .01; ****P < .0001) [Color figure can be viewed at wileyonlinelibrary.com]
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fraction (P = .0098) accompanied by an elevated fraction of cells in the
G2-phase of the cell cycle (P = .0074). Similar results were obtained by
the AMG232 treatment (Figure 3F), which also caused a reduced
S-phase fraction (48 hours: P = .008, 72 hours: P = .049) accompanied
by a reduced G1-phase after 72 hours (P = .0027) and an elevated frac-
tion of G2 (Figure 3F, P < .0001). Finally, cells with an mdm2 k.d. and
those exposed to mdm2 targeting with AMG232 showed a delayed and
retarded scratch overgrowth in the wound-healing assay (Figure 3G,H),
which is compatible with the reduced FAK activity.
3.6 | DFS and OS of patients suffering from
Luminal BC with an mdm2 gain is poor compared to
those without a gain
Microscopic images of mdm2/cen12 FISH specimens scored 1, 2 or 3 are
exemplarily shown in Figure S2. Patients withmdm2 gain showed a signifi-
cantly poor DFS (Figure 4; HR = 1.80 [95% confidence interval (CI):
1.16-2.79], log rank P = .008) and OS (HR = 1.75 [95% CI: 1.00-3.05, log-
rank P = .047) compared to the patients without mdm2 gain in the entire
Luminal BC cohort. Similar results were observed in patients with
Luminal-A BC (DFS: HR = 2.56 [95% CI: 1.40-4.71], P = .002; OS:
HR = 3.27 [95% CI: 1.51-7.09], log-rank P = .002) but not within the
Luminal-B subcohort (DFS: HR = 1.16 [95% CI: 0.60-2.26], log-rank
P = .653; OS: HR = 0.95 [95% CI: 0.41-2.23], log-rank P = .911). Thus, an
unfavorable impact of anmdm2 gain on survival outcome within the entire
Luminal BC cohort is mainly caused within the Luminal-A BC cohort.
3.7 | Patients suffering from Luminal BC with
mdm2 gain (Score 2 or 3) show a higher complete
pathological response rate but a worse DFS and OS
Overall, 53 (10.5%) of all Luminal BC patients included in our study
experienced a complete pathological response (pCR) rate upon neo-
adjuvant treatment (Table S4). With respect to mdm2, the pCR rate of
F IGURE 4 DFS and OS in patients with mdm2 gain vs no gain (ie, normal). Kaplan-Meier graphs illustrating course and outcome of Luminal
BC disease as a function of mdm2 gene amplification (Score 2 and 3) vs no amplification (Score 1) without and upon separation of Luminal-A vs
Luminal-B BC as annotated. Both, DFS and OS was poor in association with an mdm2 gain in the total cohort (DFS P = .008, OS P = .047). Upon
differentiation of Luminal-A vs Luminal-B cases statistical significance remained present for the Luminal-A cohort (DFS P = .002, OS P = .002)
but not for Luminal-B cohort (DFS P = .653, OS P = .911)
F IGURE 5 Odds ratio of pCR and HRs of DFS and OS of Luminal
BC patients as a function of mdm2 status. Impact of an mdm2 gain on
(A) the pCR, (B) the DFS and (C) the OS of Luminal BC disease with and
without differentiation of Luminal-A vs Luminal-B. P-value less than .05
indicate a significant impact of an mdm2 gain on these parameters and
are typed bold. DFS, disease-free survival; HR, hazard-ratio; OR, odds-
ratio; OS, overall survival; pCR, pathologic complete response
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TABLE 1 Multivariate analysis for pCR, DFS and OS
Multivariate analysis for pCR #
Analysis set/parameter Category Odds ratio (OR) 95% CI P-value
All Luminal
mdm2 mdm2 gain vs normal 3.01 1.36-6.64 .007
Age, years >50 vs ≤50 0.79 0.42-1.51 .480
cT cT3-4 vs cT1-2 0.87 0.42-1.81 .705
cN cN+ vs cN 0.90 0.47-1.70 .739
Grading G3 vs G1-2 2.02 1.05-3.86 .034
Histotype Nonductal vs ductal invasive 0.56 0.13-2.43 .437
Luminal-A
mdm2 mdm2 gain vs normal 2.02 0.39-10.47 .401
Age, years >50 vs ≤50 0.75 0.23-2.44 .629
cT cT3-4 vs cT1-2 1.03 0.26-4.14 .963
cN cN+ vs cN 0.94 0.28-3.20 .926
Grading G3 vs G1-2 0.82 0.17-3.93 .800
Histotype Nonductal vs ductal invasive 0.86 0.10-7.15 .891
Luminal-B
mdm2 mdm2 gain vs normal 3.75 1.42-9.87 .008
Age, years >50 vs ≤50 0.80 0.36-1.76 .572
cT cT3-4 vs cT1-2 0.73 0.30-1.74 .474
cN cN+ vs cN 0.72 0.33-1.57 .409
Grading G3 vs G1-2 2.25 1.02-4.97 .044
Histotype Nonductal vs ductal invasive 0.45 0.06-3.60 .451
Multivariate analysis for DFS #
Analysis set/parameter Category HR 95% CI P-value
All Luminal
mdm2 mdm2 gain vs normal 1.71 1.08-2.71 .022
Age, years >50 vs ≤50 1.38 0.98-1.94 .068
cT cT3-4 vs cT1-2 1.91 1.33-2.74 .000
cN cN+ vs cN 1.51 1.06-2.15 .022
Grading G3 vs G1-2 0.86 0.58-1.28 .453
Histotype Nonductal vs ductal invasive 1.38 0.78-2.47 .271
Luminal-A
mdm2 mdm2 gain vs normal 2.94 1.55-5.59 .001
Age, years >50 vs ≤50 0.78 0.46-1.34 .370
cT cT3-4 vs cT1-2 1.82 1.00-3.31 .049
cN cN+ vs cN 1.10 0.63-1.92 .746
Grading G3 vs G1-2 0.98 0.50-1.91 .943
Histotype Nonductal vs ductal invasive 1.48 0.62-3.52 .380
Luminal-B
mdm2 mdm2 gain vs normal 0.99 0.49-2.00 .985
Age, years >50 vs ≤50 2.38 1.50-3.78 .000
cT cT3-4 vs cT1-2 1.90 1.19-3.04 .007
cN cN+ vs cN 1.64 1.01-2.68 .046
Grading G3 vs G1-2 0.71 0.43-1.17 .174
Histotype Nonductal vs ductal invasive 1.37 0.62-3.01 .437
Multivariate analysis for OS #
Analysis set/parameter Category HR 95% CI P-value
All Luminal
mdm2 mdm2 gain vs normal 1.39 0.77-2.50 .272
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Luminal BC patients with mdm2 gain (Score 2 or 3) was 21.2% vs 9.2%
within the group of patients without enhanced mdm2 (OR = 2.68 [95%
CI: 1.28-5.60], P = .009; Figure 5A). Similarly, the pCR rate was signifi-
cantly higher in the presence of an mdm2 gain for the Luminal-B sub-
cohort (Figure 5A; 28.6% vs 13.4%, OR = 2.56 [95% CI: 1.04-6.30],
P = .042) compared to those with an unaltered mdm2 status. This find-
ing was not significant for Luminal-A BC patients: (Figure 5A; 12.5% vs
4.6%, OR = 3.01 [95% CI: 0.77-11.81], P = .113). The HR for DFS
(Figure 5B) in the presence of mdm2 gain was also higher for all Luminal
(HR [DFS] = 1.80 [95% CI: 1.16-2.79], P = .008) and for Luminal-A
patients (HR [DFS] = 2.56 [95% CI: 1.40-4.71], P = .006). The HR
(OS) for all Luminal patients was 1.75 ([95% CI: 1.00-3.05], P = .047)
and remained significant for Luminal-A patients only (Figure 5C; HR
[OS] = 3.27 [95% CI: 1.51-7.02], P = .001).
In the multivariate analysis for pCR (Table 1), an mdm2 amplifica-
tion remained a significant predictor of pCR in all Luminal BC samples
(ie, cumulated Luminal-A and Luminal-B; OR = 3.01 [95% CI:
1.36-6.64], P = .007) and within the Luminal-B subcohort (OR = 3.75
[95% CI: 1.42-9.87], P = .008). With regards to survival outcomes the
multivariate analysis revealed that an mdm2 gain added a significant
prognostic value to the DFS (Table 1) in all Luminal BC (HR = 1.71
[95% CI: 1.08-2.71], P = .022) and in the Luminal-A only cohort
(HR = 2.94 [95% CI: 1.55-5.59], P = .001). In the multivariate analysis
for OS (Table 1) a significant negative prognostic value of elevated
mdm2 remained in the Luminal-A subcohort (HR = 3.20 [95% CI:
1.35-7.59], P = .008). An impact of patients' age was seen with
respect of DFS in the Luminal-B cohort (HR = 2.38 [95% CI:
1.50-3.78], P = .000). Patients age had a significant impact on the OS
of the total Luminal cohort (HR = 1.94 [95% CI: 1.25-3.01], P = .003)
and upon separate analysis in the Luminal-B cohort only (HR = 2.90
[95% CI: 1.63-5.71], P < .001).
3.8 | A moderate mdm2 gain (≈5 gene copy
numbers) had an unfavorable effect on Luminal-A BC
patients while an enhanced mdm2 gain (≥10 gene
copy numbers) unfavorably affects the long-term
outcome predominantly of Luminal-B BC disease
The impact of a pronounced mdm2 gene dose (ie, Score 3) on the
survival outcome of Luminal BC disease has been separately evalu-
ated (Figure S3). Kaplan-Meyer curves demonstrate that a pro-
nounced gain unfavorably affected both the DFS (HR = 2.83 [95% CI:
1.38-5.80], log-rank P = .003) and the OS (HR = 2.66 [95% CI:
1.08-6.58], log-rank P = .028) of all Luminal BC patients, however,
among Luminal-A and Luminal-B cohorts this effect remained only sig-
nificant for the DFS in Luminal-B patients (HR = 3.16 [95% CI:
1.27-7.88], log-rank P = .009).
The overall differentiation of Luminal-A and Luminal-B BC sam-
ples without (Score 1), with a moderate (Score 2) and with an
enhanced mdm2 gain (Score 3) revealed a significant unfavorable
impact of a moderate mdm2 gain both on the DFS (HR = 2.55 [95%
CI: 1.30-5.00], log-rank P = .004) and OS (HR = 3.22 [95% CI:
1.38-7.55], log-rank P = .005) but only in Luminal-A patients
(Figure S4). In contrast, a pronounced mdm2 gain takes effect only on
the DFS (HR = 3.08 [95% CI: 1.23-7.70], log-rank P = .01) in
TABLE 1 (Continued)
Multivariate analysis for OS #
Analysis set/parameter Category HR 95% CI P-value
Age, years >50 vs ≤50 1.94 1.25-3.01 .003
cT cT3-4 vs cT1-2 2.04 1.30-3.18 .002
cN cN+ vs cN 1.93 1.22-3.04 .005
Grading G3 vs G1-2 1.02 0.64-1.64 .935
Histotype Nonductal vs ductal invasive 1.05 0.48-2.29 .911
Luminal-A
mdm2 mdm2 gain vs normal 3.20 1.35-7.59 .008
Age, years >50 vs ≤50 1.29 0.64-2.60 .485
cT cT3-4 vs cT1-2 1.94 0.88-4.31 .102
cN cN+ vs cN 1.40 0.65-3.00 .388
Grading G3 vs G1-2 1.00 0.43-2.33 .997
Histotype Nonductal vs ductal invasive 1.65 0.56-4.91 .365
Luminal-B
mdm2 mdm2 gain vs normal 0.67 0.27-1.70 .400
Age, years >50 vs ≤50 2.90 1.63-5.17 <.001
cT cT3-4 vs cT1-2 1.88 1.07-3.29 .028
cN cN+ vs cN 2.02 1.10-3.71 .023
Grading G3 vs G1-2 0.81 0.45-1.46 .487
Histotype Nonductal vs ductal invasive 0.75 0.23-2.44 .634
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Luminal-B BC patients. Of note, these results should be interpreted
with caution due to the small number of events.
3.9 | The survival outcome of Luminal-B BC
disease was poor compared to the Luminal-A BC
disease regardless the mdm2 status
Without taking the mdm2 status into account Kaplan-Meyer showed
that both the DFS (HR Luminal-B to Luminal-A = 1.63 [95% CI:
1.16-2.29], log-rank P = .004) and OS (HR Luminal-B to Luminal-
A = 1.95 [95% CI: 1.26-3.00], log-rank P = .002) were poor in
Luminal-B BC patients compared to Luminal-A BC (Figure S5).
4 | DISCUSSION
The differentiation of ER-positive BC cancers to either the Luminal-A
or Luminal-B subtype is useful but insufficient for judging the patients'
individual risk to experience tumor progression and relapse. Thus,
Luminal BC requires further stratification that allows improved indi-
vidual prognosis and therapy. Here we analyzed tumor engraftment,
growth and progression in a human-like preclinical mouse model to
identify biomarkers associated with high-risk Luminal BC disease.
Essentially, we identified that an increased mdm2 gene copy number
was associated with successful tumor engraftment in humanized NSG
mice while nonengrafted tumors had basically an unaltered mdm2.
Moreover, these mice had an increased rate and size of lung metasta-
sis which was characterized by a pronounced c-Met, and CD44
expression.
A CD44high/CD24low phenotype has been repeatedly attributed
to BC stem cells with pronounced resistance to various treatments
and enhanced tumorigenicity.26 However, it is becoming more and
more obvious that this phenotype alone may not appropriately envis-
age the initiation of tumor growth, progression and metastasis.27-30
Moreover, a number of functional studies unambiguously indicate that
an elevated CD44/CD24 expression ratio taken alone is neither suffi-
ciently representative for the colony forming capacity in vitro nor for
the initiating of tumor growth in vivo.15,31,29,32 Thus, a multifactorial
phenotype and genotype that includes a variety of markers known to
be not only involved in but also to be essential for tumor stemness
can be considered more robust to predict onset of tumor growth or
tumor relapse after therapy. c-Met, CD44 and CD47 have been previ-
ously described to be part of an enhanced capacity to initiate metasta-
sis of Luminal BC in a preclinical mouse model.15 The analysis of a
small cohort of metastatic Luminal BC patients revealed that in partic-
ular the presence of CD44/c-Met/CD47 triple positive CTCs correlate
with dismal survival and increased metastasis.2 Engraftment rates of
Luminal tumors in mice (PDX) are generally low.33 Success rates less
than 5% have been reported.11 Interestingly, in our study only tumor
samples from patients with an altered mdm2, mdm4 or TP53 genotype
had the capacity to engraft in humanized mice pointing to the more
aggressive characteristic of these tumors. Moreover, using humanized
NSG based xenotransplants we found here that mice transplanted
with mdm2 amplified tumors not only showed increased tumor
growth than animals transplanted with tumors without mdm2 alter-
ation, but also they had a significantly higher rate of (lung) metastasis
(77.3% vs 16.7%). In addition, CD44 and c-Met were significantly
higher expressed in metastatic cells compared to the primary hPDX
tumor. Thus, we conclude that in addition to a pronounced CD44 and
c-Met expression an mdm2 gene amplification determines an
enhanced malignant capacity of Luminal BC cells in a preclinical
human-like in vivo setting.
Comparative low pass sequencing of DTCs and selected tumor
cells revealed mdm2Amp primary tumors harbored mdm2 amplifications
in all analyzed single cells while a number of corresponding single
DTCs isolated from BM displayed an mdm2WT genotype. Regarding
the complex genomic rearrangements on chromosome 12, it is
unlikely that DTCs have lost the mdm2 amplification after their dis-
semination. Instead, the tumor might also harbor a low frequency of
subclones without mdm2 amplification. Especially the observation in
model hPDX PT-S1, which showed exclusively mdm2WT DTCs in BM
could indicate a parallel progression of tumor cells with different
genotype.34 This suggests that hPDX models could mimic human dis-
ease in which primary tumors and DTCs have been shown to be highly
heterogeneous.35
HTM, based on cell lines or patient derived tumor xenografts
allow the evaluation of immune cell status as a function of treatment.
In our study, human T cell incidence, PD-1 expression, tumor infiltra-
tion, maturation and activation were diminished in mdm2Amp hPDX,
which additionally indicates an mdm2-dependent immune cell regula-
tion. Recent studies demonstrated a potential immune inhibitory
effect of mdm2. It has been reported, for example, that co-targeting
of the aurora kinase-A and mdm2 results in inhibited tumor growth in
a murine melanoma model and four melanoma PDX models, which
was associated with an enhanced infiltration of NK and antigen pre-
senting cells into the murine tumors.36 Thus, targeting mdm2 (eg, with
molecule specific inhibitors) in combination with other treatments
might be a promising strategy to treat Luminal BC with an mdm2 gain.
Moreover, Fang et al detected the synergistic effect of inhibiting
mdm2 with APG115 in combination with a PD-1 blockade, which
resulted in enhanced immune cell activation and infiltration of cyto-
toxic T cells. In addition, they observed polarization of M1 macro-
phages by inhibition of M2 differentiation.37 Alternatively, Zou et al
stabilized mdm2 by the deubiquitinases USP15, which reduced T cell
activation.38
Mechanistically, the interaction of mdm2 and TP53 seems to be
essential too. mdm2 is known as an antagonist to regulate both the
protein content and activity of the tumor suppressor TP53.39 As an
E3 ubiquitin ligase mdm2 induces TP53 degradation but also sup-
presses the TP53 transactivation domain and thereby attenuates the
transcriptional activity of TP53. A reduced TP53 expression and activ-
ity results in a loss of cell cycle control and a reduced ability of prolif-
erating cells to initiate the repair of DNA damages or cell death.40
Thus, the “guardian role” of TP53 becomes impaired by an excessive
presence and activity of mdm2. With view to these molecular
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mechanisms it is not surprising that mdm2 gene amplification and ele-
vated mdm2 expression levels have been formerly associated with
tumorigenesis and an increased incidence of malignant diseases.41-43
A negative prognostic impact in BC has been described as well.44
The transcription factor TP53 is not only an important player in
the regulation of cell-cycle and apoptosis but also has been shown to
manipulate the tumor-immune cell crosstalk. For example, TP53 has
been described to modulate the differentiation of macrophages
towards an antitumor M1 by preventing the immunosuppressive M2
phenotype.45 Previously, Wang et al described the effect of a second
generation mdm2 inhibitor (HDM201) in a murine syngenic mouse
model that resulted in an increased DC population, enhanced infiltra-
tion of T-bet+/Eomes+ CD8+ T cells and raised the CD8/Treg ratio.
These effects were reversed using TP53 knockout tumor cells. Fur-
thermore, the activation marker CD80 was elevated on tumor cells
associated with enhanced IFNγ release and T cell mediated tumor cell
killing.46 In addition, the generation of apoptotic cells by an inhibition
of mdm2 (as shown in our study) might cause the release of tumor
antigens, which might further boost an immunological tumor defense.
Different clinical trials using mdm2 inhibitors such as AMG232 are
ongoing (eg, acute myeloid leukemia NCT04190550; glioblastoma
NCT03107780). Solid tumor entities as ER-positive metastatic BC
with mdm2 overexpression are also being addressed.47 Moreover, the
inhibition of mdm2 and PD-1 (pembrolizumab) is being investigated in
clinical trials (NCT03611868) and novel therapeutic combinations
therapies for ER-positive BC patients are subject to preclinical studies
(anti-CDK4/6 plus anti-mdm2).48 Remarkably, mdm2 does not only
develop TP53-dependent activity but also can potentiate tumor
growth and progression TP53-independently. More specifically,
mdm2 physically interacts with the ER and can enhance its' transcrip-
tional (and thus the proproliferative) activity in an estradiol-dependent
fashion.49 Consequently, mdm2-mediated downregulation and deacti-
vation of TP53 and the mdm2-mediated direct ER-transactivation
have a mutually reinforcing effect that results in a growth advantage
of Luminal BC. Thus, the TP53-dependent and independent activities
affect growth and progression of Luminal BC.
Extending our preclinical in vivo studies on hPDX we cytogeneti-
cally detected an mdm2 gain in 10.5% of Luminal BC patients within
the GeparTrio trial.9 The gain of the mdm2 gene region detected by
FISH can be interpreted as mdm2 gene amplification since in respec-
tive tissue specimens the corresponding centromere 12 region was
never found simultaneously increased. BCs (10.5%) with mdm2 gene
amplification is in agreement with various studies by which an inci-
dence of enhanced mdm2—either on the genomic or the protein
level—in the range of 5.7% to 15.0% has been reported.39,41,50,51
Taken the whole Luminal BC cohort of our study without differentiat-
ing between Luminal-A and Luminal-B both the DFS and OS was
poorer for those patients with mdm2 amplified breast cancer. Upon
separate evaluation of Luminal-A and Luminal-B fraction this finding
remained significant and therefore valid for Luminal-A BC patients
only. In contrast, a pronounced mdm2 amplification (ie, only Score 3)
has a negative impact on the DFS only of BC patients suffering from
the Luminal-B subtype. This observation is based on a Score
3 frequency of 4.0% in Luminal-B BC, which is just slightly higher than
in the Luminal-A cohort (2.4%). Accordingly, the missing significance
of an enhanced mdm2 gain (ie, Score 3) on the course of disease of
Luminal-A BC patients might be due to the low number of those cases
within this subcohort. However, it can be speculated that within the
Luminal-B cohort only an enhanced (but not a moderate) gain has an
extra impact on the course of disease, because this BC subtype inher-
ently comes with a poorer prognosis compared to the Luminal-A patient
group, an observation that has been repeatedly reported formerly.52
The clinical appearance of Luminal-A BC has been frequently associated
to a rather high ER-expression, while the Luminal-B type shows less ER-
expression but an enhanced proliferation activity, typically represented
by higher Ki67 values.3,6 Accordingly, a favorable and unfavorable long-
term outcome of the Luminal-A vs Luminal-B BC subgroups within the
GeparTrio study, which was mdm2 independent, has been confirmed in
our study (Figure S5). However, we here generated evidence that also
an mdm2 dose-dependent effect takes place in Luminal-B BC. One can
assume that the higher the mdm2 protein expression is the more effi-
cient is the deactivation of TP53, which might correlate with an
enhanced tumor cell viability. This consideration is supported by previ-
ous studies that addressed the impact of the mdm2 gene dose, the
extent of mdm2 protein expression and the cellular localization.44,53
The long-term outcome in our study was generally disadvanta-
geous for patients suffering from tumors with an mdm2 gene amplifi-
cation although the pCR rates were significantly higher for these
patients compared to the cohort without an mdm2 gain (Figure 5).
This finding is valid for the total Luminal BC cohort from the
GeparTrio trial subjected to our study and upon Luminal-A/Luminal-B
separation for Luminal-B BC patients. An enhanced primary effect of
cytotoxic treatments in Luminal BC with mdm2 amplification might
again be explained by higher proliferation capacity of responsive
tumors that is further enhanced by an elevated presence of mdm2.
However, an initially better pCR that does finally not result in an
improved outcome (OS) of disease, an observation that might be due
to a very long observation time of the course of disease that was
200 months in our study (Figure 5). However, different therapy regi-
mens were not considered in our study as the treatment adaptation
due to an insufficient response that improved DFS and OS of patients
with hormone receptor positive BC. Both aspects could potentially
explain the individual neoadjuvant treatment response vs long-term out-
come.9,54 Nevertheless, a pronounced mdm2 gene dose (ie, Score 3) is
associated to a better initial treatment response but seems on long-term
to be somehow involved in an unfavorable outcome. Even though
Luminal BC is basically characterized by an advantageous prognosis suf-
fering from this BC subtype it is considered as a long-term disease that
tends to progress by relapse or metastasis rather later not sooner. An
mdm2 activity might contribute to such a late progress of disease.
In conclusion, an mdm2 gene amplification facilitates growth and
progression of estrogen receptor-positive BC growth in a preclinical
xenograft humanized NSG mouse model. mdm2 inhibition in vitro
reduced malignant cell proliferation and migration and induced tumor
cell apoptosis. In addition, an mdm2 gain is strongly associated with
an unfavorable outcome of Luminal BC disease. Prospective studies
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are required to verify the suitability of mdm2 for advanced Luminal
BC stratification and therapeutic targeting.
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